Jessica Hanna
Family · Broussard, LANPI 1447903695
Payments from drug & device makers
Across 109 payments — averaging $16.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$345
- Novo Nordisk$227
- Amgen$221
- Boehringer Ingelheim$148
- GSK$87
- Lilly USA, LLC$84
- plus $683 from 18 others
What the payments were for
- Food & beverage$1,795100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 24 | $345 |
| Novo Nordisk | 14 | $227 |
| Amgen | 14 | $221 |
| Boehringer Ingelheim | 9 | $148 |
| GSK | 3 | $87 |
| Lilly USA, LLC | 5 | $84 |
| Novartis | 4 | $74 |
| Bayer | 5 | $73 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $68 |
| Pfizer | 4 | $66 |
| Ardelyx, Inc. | 3 | $55 |
| Exact Sciences | 3 | $52 |
| Insulet Corporation | 3 | $51 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $33 |
| Tolmar, Inc. | 2 | $32 |
| Edwards Lifesciences | 1 | $32 |
| AstraZeneca | 2 | $29 |
| Dexcom, Inc. | 1 | $22 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Merck | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $14 |
How this compares
$1,795 in reported general payments places this provider in the 70th percentile of 3,610 family providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 117 | $160,247 |
| JardianceEmpagliflozin | 152 | $137,877 |
| OzempicSemaglutide | 58 | $75,684 |
| EliquisApixaban | 88 | $74,599 |
| FarxigaDapagliflozin Propanediol | 62 | $71,318 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 59 | $47,414 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 54 | $47,388 |
| TrulicityDulaglutide | 21 | $36,961 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 25 | $30,858 |
| LinzessLinaclotide | 48 | $27,501 |
| XareltoRivaroxaban | 21 | $24,675 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 26 | $20,832 |
| TradjentaLinagliptin | 19 | $19,765 |
| EntrestoSacubitril/Valsartan | 18 | $18,977 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $16,318 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr, Trijardy Xr, Stiolto Respimat, Tradjenta | $148 | $262,553288 claims |
| Lilly USA, LLCMounjaro, Trulicity | $84 | $197,208138 claims |
| Novo NordiskOzempic, Novolog | $227 | $78,52074 claims |
| PfizerEliquis | $66 | $74,59988 claims |
| AstraZenecaFarxiga | $29 | $71,31862 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $87 | $56,76376 claims |
| AbbVieLinzess | $345 | $27,50148 claims |
| NovartisEntresto | $74 | $18,97718 claims |
| Astellas Pharma US IncMyrbetriq | $14 | $9,21918 claims |
| MerckJanuvia | $18 | $6,93514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,610 family providers in Louisiana.
Other family in Broussard
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
- Tiffany RoeShreveport$97K
- Ghenet GhebretatiosBaton Rouge$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.